Connect Biopharma’s (CNTB) Buy Rating Reiterated at HC Wainwright

Posted by Brenda Bartman on Oct 8th, 2026

Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Thursday, MarketBeat reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

A number of other analysts have also issued reports on the company. Oppenheimer cut their target price on Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 22nd. Piper Sandler started coverage on Connect Biopharma in a research report on Friday, June 26th. They issued an “overweight” rating and a $7.00 target price on the stock. BTIG Research cut their target price on Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Wall Street Zen raised Connect Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings raised Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Connect Biopharma has an average rating of “Moderate Buy” and an average price target of $6.14.

View Our Latest Stock Report on CNTB

Connect Biopharma Trading Down 2.8%

Shares of NASDAQ CNTB traded down $0.03 during midday trading on Thursday, reaching $0.92. 521,195 shares of the stock were exchanged, compared to its average volume of 1,437,193. The company has a 50 day simple moving average of $1.83 and a 200 day simple moving average of $2.23. The stock has a market capitalization of $57.81 million, a P/E ratio of -0.77 and a beta of -0.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37. Connect Biopharma has a twelve month low of $0.85 and a twelve month high of $3.82.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. The firm had revenue of $2.75 million for the quarter, compared to analyst estimates of $0.74 million. As a group, equities analysts expect that Connect Biopharma will post -1.09 earnings per share for the current year.

Institutional Investors Weigh In On Connect Biopharma

Institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC purchased a new stake in shares of Connect Biopharma during the 1st quarter worth $1,945,000. Bank of America Corp DE purchased a new stake in shares of Connect Biopharma in the first quarter valued at about $41,000. Knott David M Jr increased its stake in shares of Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after acquiring an additional 187,835 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Connect Biopharma during the first quarter worth about $135,000. Finally, Richmond Brothers Inc. acquired a new position in Connect Biopharma during the fourth quarter worth about $489,000. 58.72% of the stock is owned by hedge funds and other institutional investors.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.